Adding an immunotherapy drug to standard treatment for locally advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests whether adding a new immunotherapy drug, envafolimab, to standard chemotherapy and radiation can improve outcomes for patients with locally advanced cervical cancer. You may receive the experimental drug along with your usual treatment, which could help your body fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- Your cervical cancer is locally advanced (has not spread to distant organs) and you have not had surgery, radiation, or chemotherapy for it before.
- You are generally well enough to carry out daily activities (ECOG score 0-1) and your doctor expects you to live at least 12 more weeks.
- You can provide a tissue sample (biopsy) for testing.
- Your heart, liver, kidneys, and blood counts are within acceptable ranges for this study, and you are able to undergo brachytherapy (internal radiation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs with standard chemotherapy before surgery for cervical cancer that has not spread far. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy before surgery for locally advanced cervical cancer. It aims to shrink tumors and improve outcomes for patients who haven't had prior systemic treatment.
This trial tests adding a new immunotherapy drug (cadonilimab) to standard chemotherapy before surgery for locally advanced cervical cancer. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
This trial tests a new drug (QL1706) combined with chemotherapy before the usual radiation therapy for locally advanced cervical cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemoradiation for locally advanced cervical cancer caused by HPV. It may be an option for women with stage 3-4A disease or positive lymph nodes who have not had immunotherapy before.
Hear when a new Locally Advanced Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.